The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

Conditions

• Dermal Hypersensitivity Reaction

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Dupilumab — DRUG
  Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24. In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks.

Study Details

This research is studying a drug called dupilumab to learn about its safety and its effect as a treatment for participants with dermal hypersensitivity reaction. This study will help better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might help treat this condition.

Key Dates

Start date

Oct 2, 2023

Status verified

Dec 2025

Primary completion

Jan 7, 2025

Completion

Mar 25, 2025

Study Design

Enrollment

10 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Dupilumab
  All patients will receive dupilumab.

Primary Outcome Measure

Change in Th2 immune cell population in lesional Dermal hypersensitivity reaction (DHR) skin at week 16 compared to week 0. [ Time Frame: Week 0, week 16 ]

Locations (1)

Find similar trials in Ann Arbor, MI